APSR2026-793

 
Late-Breaking
Submitted
Oral Presentation
AO30-003
 
 
https://storage.unitedwebnetwork.com/files/1285/1220937-46903-APSR-793_440049.pptx
Format: PPTX Only
 
Format: PDF Only
16. Interstitial Lung Disease
4

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Kezreen Kaur Dhaliwal * Institut Perubatan Respiratori(IPR) Respiratory Department Kuala Lumpur Malaysia
Nik Nur Amirah Nik Abeed - Institut Perubatan Respiratori(IPR) Respiratory Department Kuala Lumpur Malaysia
Nurul Aimi Abd Ghani - Institut Perubatan Respiratori(IPR) Respiratory Department Kuala Lumpur Malaysia
Syazatul Syakirin Sirol Aflah - Institut Perubatan Respiratori(IPR) Respiratory Department Kuala Lumpur Malaysia
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Kezreen Kaur
Dhaliwal
kezreen3@gmail.com
+60125491248
31-40
Malaysia
Original Research
Decoding the decline: Clinical phenotypes and risk trends in progressive pulmonary fibrosis (PPF) cohort in single centre experience
Maximum 25 words
Abstract Content
Progressive pulmonary fibrosis (PPF) is an aggressive form of non-idiopathic pulmonary fibrosis (non-IPF) interstitial lung diseases (ILDs) that gets worse clinically and on imaging even with standard treatment. Our objective was to delineate the clinical phenotype, progression timeline, and treatment modalities of PPF patients.
This retrospective observational study assessed ILD patients with PPF at the Institut Perubatan Respiratori (2017–2026). Clinical, serological, and radiological parameters were examined for their correlation with early progression. Patients were categorized into early (≤19 months) and late (>19 months) progressors according to the interval from initial ILD diagnosis to PPF development.
In a cohort of 76 patients (mean age 62.8 years; 59% female; 47% Malay; ever smoking 18.4%), the autoimmune-dominant ILD phenotype was the predominant underlying diagnosis (46%), followed by connective tissue disease-associated ILD (37%), hypersensitivity pneumonitis (13%) and others (4%). HRCT mostly showed a non-UIP pattern (80%), the most common autoantibodies found were anti-Ro52 (24%) and anti-Scl-70 (17%). Immunosuppressive therapy was used in 65 patients (86%) and nintedanib initiated in 67 patients (88%). The median duration until the onset of PPF was 19 months (IQR 28). Clinically meaningful trends towards early progression were noted in patients aged ≥65 years (p=0.065, OR=2.64), smoking (p=0.375, OR=2.05), baseline FVC ≤50% (p=0.41, OR=1.73)and anti-Ro52 positivity (p=0.79, OR=1.34); however, these findings did not achieve statistical significance.
Our findings highlight a high prevalence of autoimmune-dominant ILD alongside with imaging of non-UIP patterns. Advanced age, smoking, reduced baseline lung function, and anti-Ro52 positivity emerged as markers for accelerated disease. While these findings did not reach statistical significance, they represent clinically meaningful trends that facilitate the identification of high-risk phenotypes requiring vigilant monitoring and earlier therapeutic intervention.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
progressive pulmonary fibrosis, interstitial lung disease, nintedanib
maximum 3 keywords and no abbreviations, separated by commas
Nil
294